The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations

Gefitinib is an essential drug for NSCLC patients harboring EGFR sensitive mutations. The approved dose 250mg/day is based on limited clinical trials, this research aims to explore the relationship between drug exposure and gefitinib response. C(trough) of 87 NSCLC patients harboring EGFR sensitive...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Sci Rep
Asıl Yazarlar: Xin, Shuang, Zhao, Yuanyuan, Wang, Xueding, Huang, Yan, Zhang, Jing, Guo, Ying, Li, Jiali, Li, Hongliang, Ma, Yuxiang, Chen, Lingyan, Hu, Zhihuang, Huang, Min, Zhang, Li
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4521154/
https://ncbi.nlm.nih.gov/pubmed/26228025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep12675
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller